- A pioneer in hybrid SPECT/CT imaging technology, GE Healthcare has continued the momentum of technology advancements to its SPECT/CT platform, the Infinia Hawkeye series, culminating in its latest model, the Infinia Hawkeye HD Enhanced
- Infinia Hawkeye HD Enhanced delivers up to 50% lower NM patient dose than standard cardiac and bone protocols and low CT dose ranging 0.1 – 1.7 mSv for attenuation correction and localization purposes
- 240 published citations support the positive impact of Infinia Hawkeye technology on patient management
- Over 1300 installations of Infinia Hawkeye technology worldwide, with over 500,000 patients scanned annually
WAUKESHA, WI, October 11, 2010- A pioneer in hybrid SPECT/CT imaging technology, GE Healthcare was first to bring to market a hybrid SPECT/CT product, the Hawkeye series, in 1999. With the ability to combine the power of anatomical (CT) and functional/molecular (SPECT) imaging, the Infinia Hawkeye series helps provide greater diagnostic confidence in localization of disease. To date, this technology is in operation in more than 1,300 health care settings around the world, scanning more than 500,000 patients each year.
Focused on responsible dose management and reinforcing its “healthymagination” initiative, GE Healthcare has continued to maintain the flow of innovations to the Infinia Hawkeye series, culminating in its latest model, the Infinia™ Hawkeye™ HD Enhanced. the Infinia Hawkeye HD Enhanced offers the ability to deliver up to 50 percent lower NM patient dose than standard cardiac and bone protocols and low CT dose ranging 0.1 – 1.7 mSv for attenuation correction and localization purposes.
Further, due to reduced siting requirements, reduced scan time and one of the industry’s lowest hybrid SPECT/CT cost of ownership, the Infinia Hawkeye HD Enhanced enables access to the hybrid SPECT/CT imaging technology to more patients. And, with the highest documented and published hybrid SPECT/CT imaging impact on patient management, Infinia Hawkeye 4 helps enhance clinician confidence and is proven to change clinical interpretation in an average of 35 percent of SPECT/CT cases when compared to SPECT alone.
“The advances we’ve made to the Infinia Hawkeye platform continue to provide our customers outstanding diagnostic confidence,” said Nathan Hermony, general manager, Nuclear Medicine, GE Healthcare. “We look forward to continuing our momentum of technology advancements that will help clinicians understand disease from the beginning.”
The Infinia Hawkeye HD Enhanced’s SPECT helps doctors focus on metabolic abnormalities that are present earlier than the anatomical changes can be seen with CT alone. Allowing registration of both images for a comprehensive pathology picture in a single exam, Infinia Hawkeye 4 helps physicians eliminate guesswork and enable them to plan better patient treatment.
Infinia Hawkeye HD Enhanced CT allows delivery of reduced effective dose to patients and may save patients from repeated and possibly unnecessary diagnostic CT scans through the help of the Volumetrix™ IR, which accurately registers Infinia SPECT studies to external CT scans of the same patient using the Hawkeye CT scan as a bridge. Further, with its Evolution™ application, the Infinia Hawkeye 4 delivers uncompromised SPECT and NM scan image quality at one-half the standard injectable dose.
A productivity workhorse, GE Healthcare’s Infinia Hawkeye HD Enhanced incorporates flexible and proven workflow technology advancements to help save time and costs by helping reduce total scan cycle time. Combining Ignite™, DICOM worklist, fully IHE compliant MPPS (Modality Performance Procedure Step) with flexible “free-geometry” gantry, Infinia Hawkeye 4 streamlines the workflow by automating the setup, imaging, reporting and archiving process.
Benefitting from advanced applications first introduced on the Discovery NM/CT 670, the Infinia Hawkeye 4 also offers Cardiac Morphing™ and Volumetrix™ MI, further expanding the capabilities of this advanced hybrid solution. The Infinia Hawkeye 4 innovations are based on GE Healthcare’s Evolution family of products, first available on the Discovery NM/CT 670.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.
Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality and efficiency around the world. Headquartered in the United Kingdom, GE Healthcare is a $16 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.